Celcuity Inc. CELC
At closeNov 5, 2026, 4:52 PM EST
After hours · Nov 5, 4:52 PM ET
- YTD
- -35.79%
- 1 year
- -14.14%
- Market cap
- 3.13B
- EPS (ttm)
- -4.31
- Shares out
- 48.93M
- Forward P/E
- -130.39
- YTD return
- -35.79%
- 1-year return
- -14.14%
- Volume
- 1.42M
- Avg volume
- 1.20M
- Open
- 68.28
- Previous close
- 69.24
- Day's range
- 63.44 – 68.77
- 52-week range
- 53.54 – 151.02
- Beta
- 0.13
- Analysts
- Strong Buy
- Price target
- 152.72 (+138.5%)
- Earnings date
- Nov 5, 2026
5D -4.86 (-7.05%)
Key statistics
- Enterprise value
- 3.39B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -72.00M
- Total cash
- 754.04M
- Total debt
- 754.39M
- Return on equity
- -1433.70%
- Short % of float
- 31.43%
- 50-day average
- 76.26
- 200-day average
- 100.07
Analyst view
Consensus: strong buy
- Target (low)
- 130.00
- Target (mean)
- 152.72
- Target (high)
- 177.00
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -1.54.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -1.51 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -1.16 | -1.44 | -0.28 | -24.14% |
| May 14, 2026 | Mar 31, 2026 | -1.04 | -0.97 | +0.07 | +6.73% |
| Mar 25, 2026 | Dec 31, 2025 | -1.06 | -0.97 | +0.09 | +8.49% |
| Nov 12, 2025 | Sep 30, 2025 | -1.02 | -0.92 | +0.10 | +9.80% |
| Aug 14, 2025 | Jun 30, 2025 | -0.90 | -1.04 | -0.14 | -15.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Oct 21, 2026 | TD Cowen | reit | Buy | Buy |
| Sep 30, 2026 | Needham | main | Buy | Buy |
| Sep 17, 2026 | JP Morgan | init | — | Overweight |
| Aug 17, 2026 | Guggenheim | main | Buy | Buy |
| Aug 17, 2026 | Citizens | reit | Market Outperform | Market Outperform |
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celcuity.com
News
Celcuity Q3 2026 Earnings Call Transcript 
Celcuity Q3 Adj. EPS $(1.21) Beats $(1.43) Estimate, Sales $0.00 Miss $1.563M Estimate 
Celcuity To Participate in Upcoming Investor Conferences 
Celcuity: Stronger Clinical Evidence, Much Lower Valuation 
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call 
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 
Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140 
New Strong Sell Stocks for October 14th 
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Your note
Sign in to keep a note on CELC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Unknown | Sale | Jul 13, 2026 | 0 |
| BULLER RICHARD E | Director | Stock Award(Grant) | Jun 4, 2026 | 9,319 |
| DALVEY DAVID F | Director | Stock Award(Grant) | Jun 4, 2026 | 66,530 |
| FURCHT LEO M.D. | Director | Stock Award(Grant) | Jun 4, 2026 | 12,530 |
| HAHNE VICKY | Chief Financial Officer | Stock Award(Grant) | Aug 13, 2026 | 37,808 |
| LAING LANCE G PH.D. | Officer and Director | Stock Award(Grant) | Aug 13, 2026 | 1,271,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 16.18% | 7,915,792 | 505.74M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 6.95% | 3,400,000 | 217.23M | Jun 29, 2026 |
| RTW Investments LP | 6.75% | 3,304,903 | 211.15M | Jun 29, 2026 |
| Perceptive Advisors Llc | 6.53% | 3,197,200 | 204.27M | Jun 29, 2026 |
| Blackrock Inc. | 6.17% | 3,018,785 | 192.87M | Jun 29, 2026 |
| State Street Corporation | 4.00% | 1,955,304 | 124.92M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.85% | 1,394,056 | 89.07M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.45% | 1,197,169 | 76.49M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.04% | 996,070 | 63.64M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.32% | 648,060 | 41.40M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.98% | 479,203 | 30.62M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.89% | 436,212 | 27.87M | Jun 29, 2026 |